ERAS vs GMAB Stock Comparison

GMAB currently leads ERAS in this stock comparison, with AIQ scores of 77 vs 61. The clearest difference is momentum.

Market data as of Nov 15, 2026 market close· AIQ score gap 16 points
ERAS
Healthcare
vs
GMAB
Healthcare
ERAS
Erasca, Inc.
Price
$15.66
Day move
-0.76%
AIQ Score
61/100
Best edge
Balanced
Sector
Healthcare
GMAB
Genmab A/S
Leads
Price
$51.37
Day move
-0.72%
AIQ Score
77/100
Best edge
Momentum
Sector
Healthcare

What is the main difference between ERAS and GMAB?

GMAB leads the current stock comparison as Genmab A/S, with the clearest separation coming from momentum and the broader AIQ evidence mix.

AlgovestIQ AIQ Comparison

Erasca, Inc. vs Genmab A/S

Data as of Nov 15, 2026· market close· Healthcare· Coverage 60/66 fields· High confidence
AIQ VerdictCompetitiveAIQ Comparison Conviction 8/10

GMAB leads

GMAB leads by 16 AIQ points, primarily on Momentum and Risk Resilience, but the lead has narrowed from 36 points over 30 sessions.

Competitive: 4 of 4 evidence groups support GMAB, its lead is narrowing, and its current signal state is conflicted.

Evidence agreement: 4 of 4Comparison trend: Weakening
ERAS

Erasca, Inc.

AIQ Score
61/100
AIQ Edge Score
10/10
GMAB

Genmab A/S

Leads
AIQ Score
77/100
AIQ Edge Score
10/10

The Algovestiq AIQ Score currently favors GMAB over ERAS, 77 versus 61 as of Nov 15, 2026. GMAB's advantage is driven primarily by stronger momentum and risk resilience. GMAB also shows the stronger technical structure relative to its 50-day moving average. 4 of 4 covered evidence groups favor GMAB today, and the comparison is rated Competitive on stability: the leader's advantage has been narrowing. GMAB lead: Weakening — the AIQ differential moved from 36 to 16 points over 30 sessions.

Compare Erasca, Inc. and Genmab A/S across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.

Currently unavailable

Performance over time

Price return from daily closes; distributions are not included.

ERAS
-20.7%
GMAB
+20.6%

Price return comparison

Growth of $10,000, price only

ERAS $7,929 · GMAB $12,062

Split-adjusted closes only. Distributions are excluded, which understates the return of any fund or stock that pays them.

Compare ERAS and GMAB against another ticker

Open a multi-ticker workspace without changing this focused pair page.

Basic: 2 symbols·Explorer: 3 symbols·Pro and Premium: 5 symbols·Your limit: 2

AIQ Factor Divergence

Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.

ERAS advantage
0
GMAB advantage
  • Momentum67 vs 94
    GMAB +27
  • Risk Resilience39 vs 58
    GMAB +19
  • Quality65 vs 72
    GMAB +7

4 of 4 evidence groups favor GMAB. GMAB’s edge is concentrated in momentum and risk resilience.

What changed since the last close

Latest scored session 2026-11-13, compared against the prior scored session 2026-11-12.

ERAS+9 AIQ

Largest factor move: Quality +21

New signals

  • ADX Trend Weakening — neutral, trend, medium horizon
  • Accumulation Pattern — bullish, volume, medium horizon (1.70x)
GMAB-1 AIQ

No factor moved materially.

New signals

  • Low Volume Rally Warning — bearish, volume, short horizon (0.57x)

GMAB's lead narrowed by 10 AIQ points in the latest session.

Deeper signal detail for each name lives on its own signals page — ERAS and GMAB both carry a full feed there.

Which one fits your objective

The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.

Balanced

GMAB

GMAB on the overall AIQ Score, which weights Quality and Value most heavily.

Growth

GMAB

GMAB on combined revenue and EPS growth.

Value

Even

The two are level on Value.

Momentum

GMAB

GMAB on the Momentum factor, by 27 points.

Lower downside

GMAB

GMAB on Risk Resilience, by 19 points.

Analyst upside

Even

Analyst targets are level or not covered for both names.

AIQ vs Wall Street

Where the systematic read and the analyst consensus line up — and where they do not.

MeasureERASGMABNote
Implied upside to target—+8%Level
Target dispersion—+50.5%Lower is tighter analyst agreement
ConsensusBuyBuyContext, not a primary driver
Analysts covering913Higher coverage generally improves confidence

Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.

AIQ Agreement Matrix

4 of 4 covered evidence groups favor GMAB. A wide gap backed by one group is a weaker case than a narrow gap backed by five.

Evidence groupFavorsReading
AIQ ScoreGMAB61 vs 77
FundamentalsGMABrevenue growth 0% vs 2.8%; EPS growth -7.1% vs 14.3%; TTM ROE -5.6% vs 5.4%
ValuationNot coveredNot covered
TechnicalsGMABPrice vs 50-day 4.7% vs 24.8%; vs 200-day 2.6% vs 62.9%
Risk ResilienceGMABRisk Resilience 39 vs 58
Analyst expectationsNot coveredNot covered

✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of ERAS and GMAB and are excluded from the count.

AIQ Decision Stability

Competitive

The two are close enough that your objective, not the score, should decide.

  • The AIQ gap is wide at 16 points. (supports the conclusion holding)
  • 4 of 4 covered evidence groups point the same way. (supports the conclusion holding)
  • The leader's advantage has been narrowing. (argues the conclusion is provisional)
  • The lead has swung materially session to session. (argues the conclusion is provisional)
  • The leader is throwing conflicting signals. (argues the conclusion is provisional)

Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on GMAB.

How the comparison changed

120 daily snapshots · May 27 – Nov 13

GMAB lead: Weakening — the AIQ differential moved from 36 to 16 points over 30 sessions.

May 27ERAS leads above the line · GMAB leads belowNov 13
Today
GMAB +16
61 vs 77
7 sessions ago
GMAB +28
51 vs 79
30 sessions ago
GMAB +36
41 vs 77
90 sessions ago
GMAB +9
59 vs 68

The lead has not changed hands in this window.

AIQ Signal Divergence

Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.

ERASConflicted

2 bullish / 2 bearish / 2 neutral, conflicted

Only ERAS

  • Death Cross Active — bearish, trend, long horizon (2.00%)
  • ADX Trend Weakening — neutral, trend, medium horizon
  • Accumulation Pattern — bullish, volume, medium horizon (1.70x)
  • Beta Spike Warning — bearish, risk_regime, long horizon
GMABConflicted

3 bullish / 3 bearish / 1 neutral, conflicted

Only GMAB

  • Golden Cross Active — bullish, trend, long horizon (30.48%)
  • Low Volume Rally Warning — bearish, volume, short horizon (0.57x)
  • MACD Histogram Expanding Bearish — bearish, momentum, short horizon
  • RSI Bearish Divergence — bearish, momentum, medium horizon
  • Uptrend Structure Active — bullish, trend, long horizon

Both carry 2 more signals that do not separate them: ATR Expansion - Breakout Mode, EMA Ribbon Expansion Bullish.

GMAB leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.

Price vs model alignment

Whether the latest session's price move confirms what the model did over the same session, or contradicts it.

ERASDivergence

Price is down while the AIQ Score moved up 9 points over the same session — price and model disagree (price -0.76%, AIQ +9 points).

GMABConfirmed weakness

Price and the AIQ Score both moved down over the latest session (price -0.72%, AIQ -1 points).

What would flip this result

A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.

  1. 1ERAS closes the Momentum gap — currently 27 points behind, the largest single contributor to GMAB's edge.
  2. 2ERAS's Death Cross Active resolves — a bearish trend rule currently active against it.
  3. 3GMAB's conflicting signal state resolves bearish — it currently carries 3 bullish and 3 bearish rules at once.
  4. 4The narrowing continues — the lead has already given back 20 points over 30 sessions, and a further 16-point move would eliminate GMAB's advantage entirely.

The full evidence

Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.

Fundamentals

GMAB leads on balance
MetricERASGMAB
Revenue growth (YoY)0%2.8%
EPS growth (YoY)-7.1%14.3%
Gross margin0%92.6%
Operating margin0%30.5%
Return on equity (TTM)-5.6%5.4%
Debt to equity0.050.82

Performance

Split across windows
MetricERASGMAB
1 week (5 sessions)8.7%-4.2%
1 month (20 sessions)17%38.8%
3 months (63 sessions)-14.3%56.4%
6 months (126 sessions)53.1%93.6%
Year to date321%66.8%
1 year (252 sessions)490.9%68.6%

Technicals

GMAB has the stronger structure
MetricERASGMAB
RSI (14)53.859.1
ADX (14)11.645.8
Price vs 50-day4.7%24.8%
Price vs 200-day2.6%62.9%
Volatility (1M, annualized)81.1%110.9%

Risk

GMAB is the more resilient
MetricERASGMAB
Beta1.620.93
Sharpe ratio2.291.29
Sortino ratio3.652.53
Max drawdown-59.5%-32.5%
Current drawdown-30.3%-10.3%
Annualized volatility102.7%45.9%
Value at risk (95%)-6.6%-3.2%

Straight answers

Each answer is regenerated from the current snapshot, not written once and left to age.

Which is better, ERAS or GMAB?

On the Algovestiq AIQ Score, GMAB is the stronger of the two as of Nov 15, 2026, scoring 77 against ERAS's 61. The edge comes from momentum and risk resilience. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.

Is ERAS or GMAB the better buy right now?

GMAB carries the stronger systematic profile as of Nov 15, 2026, and the comparison is rated Competitive — 4 of 4 covered evidence groups agree. A Competitive rating means the two are close enough that your objective, not the score, should decide.

Why does the AIQ Score favor GMAB over ERAS?

The composite weights Quality, Value, Momentum and Risk Resilience. GMAB leads Momentum by 27 points; GMAB leads Risk Resilience by 19 points; GMAB leads Quality by 7 points. Where the two split, the factor with the larger weight carries the result.

Which has more analyst upside, ERAS or GMAB?

Analyst price targets imply not covered upside for ERAS and +8% for GMAB. The model and the Street agree here, which is a broader base of evidence than either alone. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.

Which is better value, ERAS or GMAB?

Neither name separates on the peer-relative Value factor. The two are level on Value. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.

Which has stronger growth, ERAS or GMAB?

GMAB on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.

Which has stronger momentum, ERAS or GMAB?

GMAB on the Momentum factor, by 27 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.

Which is riskier, ERAS or GMAB?

GMAB is the more resilient of the two, so the other name carries the higher downside risk. GMAB on Risk Resilience, by 19 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.

Is ERAS more profitable than GMAB?

GMAB leads on the comparable margin measures — gross margin 0% vs 92.6%; operating margin 0% vs 30.5%; ttm roe -5.6% vs 5.4%.

Is GMAB's lead over ERAS getting stronger or weaker?

GMAB lead: Weakening — the AIQ differential moved from 36 to 16 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-05-27 and 2026-11-13. The lead has not changed hands in that window.

What would change the ERAS vs GMAB verdict?

The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: ERAS closes the Momentum gap — currently 27 points behind, the largest single contributor to GMAB's edge; ERAS's Death Cross Active resolves — a bearish trend rule currently active against it; GMAB's conflicting signal state resolves bearish — it currently carries 3 bullish and 3 bearish rules at once; the narrowing continues — the lead has already given back 20 points over 30 sessions, and a further 16-point move would eliminate GMAB's advantage entirely.

What do the current signals say about ERAS and GMAB?

ERAS: 2 bullish / 2 bearish / 2 neutral, conflicted. GMAB: 3 bullish / 3 bearish / 1 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on ERAS is Death Cross Active (bearish, long horizon). On GMAB it is Golden Cross Active (bullish, long horizon).

Compare ERAS and GMAB with others

Continue your research

This page answers which of the two. These answer the questions on either side of it.

How this comparison is scored

The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.

The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.

How to use side-by-side comparison →

This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.